Bioxcel therapeutics reports financial results for the fourth quarter and full year 2023

Provides update on two late-stage clinical programs for bxcl501 for potential treatment of agitation recently completed meetings with u.s. food and drug administration for tranquility and serenity programs c onference call and webcast set for 8:00 a.m. et today new haven, conn.

BTAI Ratings Summary

BTAI Quant Ranking